Skip to main content
Back to Top
Augusta University LogoShield

Information for:

  • Current Students
  • Alumni
  • Community
  • Faculty & Staff
  • Military
  • Patients

Resources

  • A-Z Index
  • Calendar
  • Campus Maps
  • D2L LMS
  • Email
  • Libraries
  • MyAugusta
  • News
  • Jobs & Careers
  • Portals
  • Pounce
  • Shuttles
  • Admissions
  • Academics
  • About
  • Student Life
  • Athletics
  • Research
  • Health
  •   Giving
Clinical Trials
  • Overview
  • Trials by Tumor Type
  • Our Programs
    • Georgia CaRES
    • Pediatric Immunotherapy Program
      • Overview
      • "Never Say No" Campaign
    • Trials and Timely Updates
  • Augusta University
  • Georgia Cancer Center
  • Clinical Trials
  • Clinical Trials by Tumor Type

Clinical Trials by Tumor Type

As an academic medical center, the Georgia Cancer Center in Augusta, GA is actively involved in cancer research for cancer patients.

Clinical trials are the last step in a carefully regulated, detailed scientific process that starts in a laboratory in cells or tissue and are then tested in humans - oftentimes years later and always after strenuous review.

Medical studies are supervised by a local physician and look at every stage of disease, from first diagnosis to advanced disease. All are designed to find, diagnose, treat or prevent cancer.

Contact Us

Clinical Trials Office

 Health Sciences Campus

GCC - M. Bert Storey Research Building

1410 Laney Walker Boulevard, Augusta, GA 30912

Trials by Tumor Type

Protocol # Title Study Type Department PI Name NCT # Coordinator
AU-WF-1805CD Implementation and Effectiveness Trial of HN-Star NCORP Supportive Care - Head & Neck Ghamande, Sharad NCT04208490 Hannah Claussen or Melissa Thomas
AU-URCC21038 URCC21038, Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti PD-L1 Immunotherapy in a Community Oncology Setting NCORP Observational Ghamande, Sharad NCT05364086 Kim English
AU-TEMEC Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men with Cancer and Androgen Deficiency Industry/Sponsored Supportive Care Del Fabbro, Egidio NCT04301765 Harriet Boatwright
AU-TCBIO-001-0710 (TCBIO-001-0710) The CARIS Biorepository Research Protocol Industry/Sponsored GYN/ONC - Biorespository Ghamande, Sharad NCT01499394 Alex Ward
AU-STUDY00003849 A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients with Locally Advanced or Metastatic Cervical Cancer Industry/Sponsored GYN/ONC Ghamande, Sharad NCT04865887 Emily Sarria
AU-SOVI-2302 A Phase 1b Dose Optimization Study of Sovilnesib (an Oral KIF18A Inhibitor) in Subjects with Advanced High Grade Serous Ovarian Cancer Industry/Sponsored GYN/ONC Ghamande, Sharad NCT06084416 Gwen Stanley
AU-SGNDV-005 A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2 Industry/Sponsored GYN/ONC Ghamande, Sharad NCT06003231 Melissa Berry
AU-SAL101JG A Phase I Open-Label, Multicenter Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of SAIL66 in Patients with CLDn6-Positive Locally Advanced or Metastatic Solid Tumors Industry/Sponsored GYN/ONC Ghamande, Sharad NCT05735366 Gwen Stanley
AU-S2013 Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study NCORP Observational Ghamande, Sharad NCT04871542 Kim English
AU-S1933 (S1933) A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status NCORP Thoracic Oncology Raval, Girindra NCT04310020 Kristen Learnard
AU-S1918 S1918: A Phase II/III Randomized Study of R-miniCHOP With or Without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-grade B-cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements NCORP Diffuse Large B-Cell Lymphoma Bryan, Locke NCT04799275 Savannah Crews
AU-S1912CD A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) NCORP Supportive Care Ghamande, Sharad NCT04960787 Hannah Claussen or Melissa Thomas
AU-S1827 (S1827) MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) NCORP Thoracic Oncology Ghamande, Sharad NCT04155034 Kristen Learnard
AU-S1802 (S1802) Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer NCORP GU/ONC Ghamande, Sharad NCT03678025 Ashlyn Stevenson
AU-RTOG-1216 (RTOG 1216) Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck NCORP Head & Neck Ghamande, Sharad NCT01810913 Ashlyn Stevenson
AU-PROSPECTIVE-CARDONC-REGIST Role of Social Determinants of Health and Vascular Aging as Markers of Cardiovascular Disease due to Cancer Therapy IIT Cardio-Oncology Care Guha, Avirup N/A Harikrishnan Hyman Kunhiraman
AU-PM1183-C-010-22 Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma Industry/Sponsored GYN/ONC Ghamande, Sharad NCT06088290 Emily Sarria
AU-PHRI-RADICAL-PC1 The Role of Androgen Deprivation Therapy In CArdiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1)   Cardio-Oncology Care Guha, Avirup NCT03127631 Harikrishnan Hyman Kunhiraman
AU-P9846 (P9846) Patient-derived Models Tissue Procurement Protocol for the National Cancer Institute NCORP GYN/ONC - Biorespository Ghamande, Sharad NCT02474160 Kim English
AU-NRG-HN009 Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) NCORP Head & Neck Ghamande, Sharad NCT05050162 Ashlyn Stevenson
AU-NRG-GY031 A Phase IB Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer NCORP GYN/ONC Ghamande, Sharad NCT05950464 Gwen Stanley
AU-NRG-GY028 NRG-GY028: A Phase IIB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer NCORP GYN/ONC Ghamande, Sharad NCT05538897 Katie Dorr
AU-NRG-GY027 Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805 NCORP GYN/ONC Ghamande, Sharad NCT05276973 Gwen Stanley
AU-NRG-GY026 A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma NCORP GYN/ONC Ghamande, Sharad NCT05256225 Melissa Berry
AU-NRG-GY025 A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma NCORP GYN/ONC Ghamande, Sharad NCT05112601 Gwen Stanley
AU-NRG-GY019 (NRG-GY019) A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum NCORP GYN/ONC Ghamande, Sharad NCT04095364 Gwen Stanley
AU-NRG-GI004 (NRG-GI004/SWOG-S1610) Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer NCORP GI Cancer Ghamande, Sharad NCT02997228 Ashlyn Stevenson
AU-NRG-CC012CD NRG-CC012CD: Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment (SYMON) NCORP Non-Treatment Ghamande, Sharad NCT06279013 Hannah Claussen or Melissa Thomas
AU-NRG-CC008 A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] NCORP GYN/ONC Ghamande, Sharad NCT04251052 Kim English
AU-NRG-BN011 NRG-BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma NCORP Neuro-Oncology Wallace, Gerald NCT05095376 Morgan Williams
AU-NMTRC014 NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO); NMTRC014 Industry/Sponsored Pediatric HEM/ONC - Neuroblastoma McDonough, Colleen NCT02679144 Caryn Bird
AU-NMTRC012 PEDS-PLAN - Pediatric Precision Laboratory Advanced Neuroblastoma Therapy - A Study Using Molecular Guided Therapy with Induction Chemotherapy Followed by a Randomized Controlled Trial of standard Immunotherapy with or without DFMO Followed by DFMO Maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma Industry/Sponsored Pediatric HEM/ONC - Neuroblastoma McDonough, Colleen NCT02559778 Caryn Bird
AU-NKT3447-101 A Phase 1, First-In-Human, Open-Label Study to Evaluate the Safety, Tolerability, Pk, and Preliminary Anti-Tumor Activity of the Novel Orally Available Cdk2 Inhibitor NKT3447 in Adults with Advanced/Metastatic Solid Tumors Industry/Sponsored Solid Tumor Ghamande, Sharad NCT06264921 Katie Dorr
AU-NEO100-01 An Open-Label, Phase 1/2a Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or IV Gliomas with IDH1 Mutation Industry/Sponsored Neuro-Oncology Wallace, Gerald NCT02704858 Morgan Williams
AU-MPCT-012L A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Industry/Sponsored Non-Hodgkin Lymphoma Bryan, Locke NCT05826535 Mandy Spires
AU-MORAB-202-G000-201 A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRa)-Targeting Antibody-Drug Conjugate (ADC) in Subjects with Selected Tumor Types Industry/Sponsored Solid Tumor Ghamande, Sharad NCT04300556 Katie Dorr
AU-MK-2870-005 A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095) Protocol Number: 005-01/ENGOT-en23/GOG-309 Industry/Sponsored GYN/ONC Ghamande, Sharad NCT06132958 Melissa Berry
AU-MDS-AML-REGISTRY Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry Industry/Sponsored HEM/ONC - Registry Mian, Mohammad NCT01688011 Gita Giddens or Sharmin Khan
AU-M-2018-344 A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma Industry/Sponsored Diffuse Large B-Cell Lymphoma Kota, Vamsi NCT04792489 Amanda Spires
AU-LUNG-MAP (LUNG-MAP) A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) NCORP Thoracic Oncology Raval, Girindra NCT03851445 Kristen Learnard
AU-KT-US-484-0136 An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma Industry/Sponsored Large B-Cell Lymphoma Kota, Vamsi NCT05605899 Becky Paynter
AU-KO-MEN-007 Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia Industry/Sponsored Acute Myeloid Leukemia Cortes, Jorge NCT05735184 Mandy Spires
AU-J2J-MC-JZLH A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2-Early Breast Cancer with an Increased Risk of Recurrence Industry/Sponsored Breast Cancer Raval, Priyanka NCT05514054 Morgan Williams
AU-IOV-LUN-202 (LN-145) A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer Industry/Sponsored Thoracic Oncology Kota, Vamsi NCT04614103 Kristen Learnard
AU-IM048022 A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) Industry/Sponsored Multiple Myeloma Keruakous, Amany NCT05827016 Sarah Leathers
AU-HQP1351CU101 A Phase Ib Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered Hqp1351 in Subjects With Refractory Chronic Myeloid Leukemia (CML) And Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) Industry/Sponsored Chronic Myeloid Leukemia Cortes, Jorge NCT04260022 Thalyta Freitas
AU-HPV-VAC-PP (HPV-VAC-PP) Immunogenicity, Compliance, Knowledge and Attitudes in Postpartum Women during a Two Dose 9-valent HPV Vaccination Series Industry/Sponsored Prevention - HPV Zahler-Miller, Carolyn NCT04311528 Angela Goebel
AU-GOG-3086 REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigators Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1) Industry/Sponsored GYN/ONC Ghamande, Sharad NCT05870748 Rebecca Scholer
AU-GOG-3083 A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma Industry/Sponsored GYN/ONC Ghamande, Sharad NCT05611931 Melissa Berry
AU-GOG-3043 A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial) Industry/Sponsored GYN/ONC Ghamande, Sharad NCT04831580 Emily Sarria
AU-GCC1953 Expanded Cccess for Indoximod in Combination With Chemotherapy for Pediatric Patients With Relapsed Brain Cancer IIT Pediatric - Brain Cancer Johnson, Theodore N/A Robin Dobbins
AU-GCC2020 Repurposing Ibrutinib for Chemo-immunotherapy in a Phase 1b Study of Ibrutinib With Indoximod Plus Metronomic Cyclophosphamide and Etoposide for Pediatric Patients With Brain Cancer IIT Pediatric - Brain Cancer Johnson, Theodore NCT05106296 Robin Dobbins
AU-GCC1949 Phase 2 Trial of Indoximod with Chemotherapy and Radiation for Children with Progressive Brain Tumors or Newly Diagnosed DIPG IIT Pediatric - Brain Cancer Johnson, Theodore NCT04049669 Robin Dobbins
AU-GCC-23-021 The Effect of Low-Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy IIT GYN/ONC Johnson, Marian Symmes NCT05980169 Katie Dorr or Rebecca Scholer
AU-GCC-23-018A Androgen Deprivation Therapy Mediated Cardiovascular Disease and Vascular Aging in Men with Prostate Cancer: Racial Difference, and Role of NAD+ IIT Cardio-Oncology Care Guha, Avirup N/A Harikrishnan Hyman Kunhiraman
AU-GCC-22-044 Evaluation of Cholecalciferol (VitD3) Maintenance Supplementation in Patients With Multiple Myeloma (MM) Undergoing Transplantation and in Combination With Lenalidomide Maintenance IIT Multiple Myeloma Keruakous, Amany NCT05846880 Megan Johnson
AU-GCC-22-037 Genetic Testing in Minorities - I (GTM-I) Towards Universal Paired Tumor/Germline Genetic Testing in Solid Tumor Patients IIT Solid Tumor Henson, John N/A John Henson, MD
AU-EA9181 (EA9181) A Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults NCORP Acute Lymphoblastic Leukemia Kota, Vamsi NCT04530565 Sarah Leathers
AU-EA6141 Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma NCORP Melanoma Ghamande, Sharad NCT02339571 Ashlyn Stevenson
AU-DCP-002 (DCP-002) Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations NCORP Biorepository Ghamande, Sharad N/A Kim English
AU-DCP-001 (DCP-001) Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) NCORP Screening Ghamande, Sharad N/A Kim English
AU-D419CR00035 An Observational Multi-Center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers Industry/Sponsored GI Cancer - Observational Nayak, Asha N/A Ashlyn Stevenson
AU-CTA-2101 Phase 1b/2a Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients with Diffuse Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy Industry/Sponsored Cytokine Release Syndrome Cortes, Jorge NCT05905328 Thalyta Freitas
AU-CB10A A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER) Industry/Sponsored B-Cell Non-Hodgkin Lymphoma Kota, Vamsi NCT04637763 Megan Johnson
AU-CABL001AUS06T Asciminib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Industry/Sponsored Chronic Myeloid Leukemia Cortes, Jorge NCT05143840 Thalyta Freitas
AU-BP1001-201-AML (BP1001-201-AML) A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) Who Are Ineligible for Intensive Induction Therapy Industry/Sponsored Acute Myeloid Leukemia Kota, Vamsi NCT02781883 Sarah Leathers
AU-BCC015 (BCC015) Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma Industry/Sponsored Pediatric HEM/ONC - Neuroblastoma McDonough, Colleen NCT04301843 Caryn Bird or Archana Laknaur
AU-BCC018 A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma Industry/Sponsored Pediatric HEM/ONC - Neuroblastoma McDonough, Colleen NCT05489887 Caryn Bird or Archana Laknaur
AU-APEC14B1 (APEC14B1) The Project: Every Child Protocol; A Registry, Eligibility, Screening, Biology and Outcome Study Industry/Sponsored Pediatric HEM/ONC - Observational McDonough, Colleen NCT02402244 Caryn Bird or Archana Laknaur
AU-AHOD2131 AHOD2131, A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immunooncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma NCORP Pediatric HEM/ONC - Observational McDonough, Colleen NCT05675410 Savannah Crews
AU-AHEP1531 (AHEP1531) Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) NCORP Pediatric HEM/ONC - Observational McDonough, Colleen NCT03533582 Caryn Bird or Archana Laknaur
AU-AGCT1531 (AGCT1531) A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors NCORP Pediatric HEM/ONC - Germ Cell Tumors McDonough, Colleen NCT03067181 Caryn Bird or Archana Laknaur
AU-AALL1732 (AALL1732) A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy NCORP Pediatric HEM/ONC - Acute Lymphoblastic Leukemia McDonough, Colleen NCT03959085 Caryn Bird or Archana Laknaur
AU-A151216 (A151216 ALCHEMIST) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) NCORP Thoracic Oncology Ghamande, Sharad NCT02194738 Kristen Learnard
AU-A052101 A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma NCORP Mantle Cell Lymphoma Bryan, Locke NCT05976763 Savannah Crews
AU-64007957MMY1008 A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma Industry/Sponsored Multiple Myeloma Keruakous, Amany NCT06425991 Megan Johnson
AU-611255 (BMT Repository) Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries Industry/Sponsored BMT - Observational Kota, Vamsi NCT04920474 Gita Giddens, Courtney Corley or Kimberly Green
AU-611164 (BMT Repository) Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries Industry/Sponsored BMT - Observational Kota, Vamsi NCT01166009 Gita Giddens, Courtney Corley or Kimberly Green
AU-587 A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab Industry/Sponsored Patients in F/U that received Pembrolizumab Ghamande, Sharad NCT03486873 Katie Dorr
AU-4010-01-001 (TESARO 4010-01-001) Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with advanced Solid Tumors Industry/Sponsored Solid Tumor Ghamande, Sharad NCT02715284 Ashlyn Stevenson
AU-2079199 Global Cardio Oncology Registry Industry/Sponsored Cardio-Oncology Care Guha, Avirup N/A Harikrishnan Hyman Kunhiraman
AU-10-CBA A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications Industry/Sponsored HEM/ONC CBU- Observational Kota, Vamsi NCT01351545 Gita Giddens, Courtney Corley or Kimberly Green
AU-TERN-701-1012 A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Myeloid Leukemia Industry/Sponsored Chronic Myeloid Leukemia Cortes, Jorge NCT06163430 Thalyta Freitas
AU-MYELOMATCH Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials NCORP HEM/ONC - Screening Kota, Vamsi NCT05564390 Sarah Leathers
AU-54767414MMY2095 Pilot Study of Daratumumab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients with Renal Failure Industry/Sponsored Multiple Myeloma Keruakous, Amany NCT06142396 Amanda Spires
AU-A051902 A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas NCORP T-Cell Lymphoma Bryan, Locke NCT04803201 Becky Paynter
AU-NXP800-101 A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer Industry/Sponsored GYN/ONC Ghamande, Sharad NCT05226507 Katie Dorr
AU-NRG-CC010 A Phase III Trial of the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer NCORP Supportive Care Ghamande, Sharad NCT05646316 Kim English
AU-MM1YA-S01 A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial NCORP Acute Myeloid Leukemia Kota, Vamsi NCT05554406 Sarah Leathers
AU-MM1OA-EA02 A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial NCORP Acute Myeloid Leukemia Kota, Vamsi NCT06317649 Sarah Leathers
AU-MA-GVHD-401 A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) Industry/Sponsored Observational Kota, Vamsi NCT05919511 Gita Giddens or Sharmin Khan
AU-S2308 Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma NCORP Follicular Lymphoma Bryan, Locke NCT06337318 Becky Paynter
AU-ARST2031 A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS) NCORP Pediatric HEM/ONC - Rhabdomyosarcoma McDonough, Colleen NCT04994132 Caryn Bird or Archana Laknaur
AU-SN-C-00014 Assessment of Chimerism and Relapse Post-Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test (ACROBAT) Industry/Sponsored BMT - Observational Kota, Vamsi NCT04635384 Harriet Boatwright
AU-S1914 (S1914) A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC NCORP Thoracic Oncology Raval, Girindra NCT04214262 Kristen Learnard
AU-MVT-601-056 Relugolix Versus Leuprolide in Patients with Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)   Cardio-Oncology Care Guha, Avirup NCT05605964 Harikrishnan Hyman Kunhiraman
AU-LTFS An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy Industry/Sponsored BMT - Observational Kota, Vamsi NCT05332054 Megan Johnson
AU-ACCL20N1CD Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States NCORP Acute Lymphoblastic Leukemia - Observational Ghamande, Sharad NCT04928599 Caryn Bird or Archana Laknaur
AU-A041501 A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL NCORP Acute Lymphoblastic Leukemia Kota, Vamsi NCT03150693 Sarah Leathers
AU-WF-2301CD WF-2301 CD: Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers NCORP Thoracic Oncology Ghamande, Sharad NCT06383988 Hannah Claussen or Melissa Thomas
AU-URCC-23086CD URCC-23086CD: Sexual Orientation and Gender Identity Data Collection in Community Oncology Practice NCORP Non-Treatment Ghamande, Sharad NCT05845476 Hannah Claussen or Melissa Thomas
AU-LND-300 (RECOVER) A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy® System as AdjunctivE Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression Industry/Sponsored Psychiatry & Health Behavior Rosenquist, Peter NCT03887715 Laryssa McCloud or Tess Dzurny
AU-1640358 Impacting Cancer Health Disparities and Facilitating Cancer Health Equity in Breast, Multiple Myeloma, and Prostate Cancers in Underserved and Minority Populations: The cancer-Community Awareness Access Research & Education II (c-CARE II) Initiative IIT Prevention Tingen, Martha N/A  
AU-AAML1831 A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations NCORP Pediatric HEM/ONC - Acute Myeloid Leukemia McDonough, Colleen NCT04293562 Caryn Bird or Archana Laknaur
AU-AGCT1532 Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours NCORP Pediatric HEM/ONC - Germ Cell Tumors McDonough, Colleen NCT02582697 Caryn Bird or Archana Laknaur
AU-ALTE03N1 Key Adverse Events after Childhood Cancer NCORP Pediatric HEM/ONC - Observational McDonough, Colleen NCT00082745 Caryn Bird or Archana Laknaur
AU-ALTE05N1 Umbrella Long-Term Follow-Up Protocol NCORP Pediatric HEM/ONC - Observational McDonough, Colleen NCT00736749 Caryn Bird or Archana Laknaur
AU-AREN03B2 Renal Tumors Classification, Biology, and Banking Study NCORP Pediatric HEM/ONC - Renal Tumors McDonough, Colleen NCT00898365 Caryn Bird or Archana Laknaur

Clinical Trial Phases

Most clinical research that involves the testing of a new drug progresses in an orderly series of steps, called phases. This allows researchers to ask and answer questions in a way that results in reliable information about the drug and protects the patients. Most clinical trials are classified into one of three phases.

Phase 1

 

These first studies in people evaluate how a new drug should be given (by mouth, injected into the blood, or injected into the muscle), how often and what dose is safe. Cancer patients who enroll in these trials have already tried other treatment options.

Phase 2

 

A phase II trial continues to test the safety of the drug, and begins to evaluate how well the new drug works. Phase II studies usually focus on a particular type of cancer and typically enrolls fewer than a hundred patients.

Phase 3

In a Phase III trial, a participant will usually be assigned to the standard group or the new group at random (called randomization). Phase III trials often enroll large numbers of people and may be conducted at many doctors' offices, clinics and cancer centers nationwide.

Phase 4

The maker of an approved drug may study it further in a phase IV trial to evaluate the side effects, risks and benefits of a drug over a longer period of time and in a larger number of people.

Enrollment Eligibility

Before a patient is enrolled in a clinical trial, the individual is carefully screened against a set of criteria designed to identify a group of people that are as similar as possible.

Qualification for a trial depends on a variety of factors including stage of disease, existing health conditions and other factors. The patient then goes through what is known as “informed consent” where the goals of the trial, why it is needed and how it will work are explained in easily understandable terms. Patients should take the time to discuss all the details of a clinical trial with their doctor and family before agreeing to participate. Questions to consider include information about costs, time commitments, and potential benefits as well as side effects. This may vary, based on where the new therapy or tool is in the development and testing process.

 

University Shield

Augusta University

1120 15th Street, Augusta, GA 30912

  •   Campus Maps
  •   Campus Contacts
  • A-Z Directory
  • Degrees & Programs
  • Employment
  • Accessibility
  • Accreditation
  • Campus Safety
  • Compliance Hotline
  • Human Trafficking Notice
  • Privacy Notices
  • Title IX / Sexual Misconduct
Apply Now Give Now

© 2025 Augusta University

Facebook Twitter LinkedIn Youtube Instagram
©